Fibrin network variability;Variabilidad de las redes de fibrina

Acta Bioquimica Clinica Latinoamericana

Volumn 41, Issue 1, 2007, Pages 7-19

  Lauricella, Ana María ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Fibrin; Fibrin properties; Fibrin formation; Fibrinogen

Indexed keywords

EID: 34548303934     PISSN: 03252957     EISSN: 03252957     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Mosesson MW. Fibrinogen and fibrin polymerization and functions. Blood Coagul Fibrinolysis 1999; 10 Suppl 1: S45-8.
2. Erickson HP, Fowler WE. Electron microscopy of fibrinogen, its plasmic fragments and polymers. Ann N Y Acad Sci 1983; 408: 146-63.
3. Weisel JW, Stauffacher CV, Bullitt E, Cohen C. A model for fibrinogen: domains and sequence. Science 1985; 230: 1388-91.
4. Fu Y, Grieninger G. Fib420: A normal human variant of fibrinogen with two extended chains. Proc Natl Acad Sci USA 1994; 91: 2625.
5. Nieuwenhuizen W. Biochemistry and measurement of fibrinogen. Eur Heart J 1995; 16: 6-10.
6. Spraggon G, Applegate D, Everse SJ, Zhang JZ, Verapandian L, Redman C et al. Crystal structure of a recombinant alphaEC domain from human fibrinogen-420. Proc Natl Acad Sci USA 1998; 95(16): 9099-104.
7. Mosesson MW. Fibrinogen gamma chain functions. J Thromb Haemost 2003; 1 (2): 231-8.
8. Wolfenstein-Todel C, Mosesson MW. Human plasma fibrinogen heterogeneity: evidence for an extended carboxil-terminal sequence in a normal gamma chain variant (γ′). Proc Natl Acad Sci USA 1980; 77: 5069-73.
9. Siebenlist KR, Meh DA, Mosesson MW. Plasma factor XIII binds specifically to fibrinogen molecules containing γ′ chain. Biochemistry 1996; 35: 10448-53.
10. Mosesson MW, Siebenlist KR, Hernandez I, Wall JS, Hainfeld JF. Fibrinogen assembly and crosslinking on a fibrin fragment E template. Thromb Haemost 2002; 87 (4): 651-8.
11. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005; 3 (8): 1894-904.
12. Kaminski M, Siebenlist KR, Mosesson MW. Evidence for thrombin enhancement of fibrin polymerization that is independent of its catalytic activity. J Lab Clin Med 1991; 117: 218-25.
13. Lorand L. Factor XIII: Structure, activation and interaction with fibrinogen and fibrin. Ann NY Acad Sci 2001; 936: 291-311.
14. Tsurupa G, Medved L. Identification and characterization of novel t-PA and plasminogen-binding sites within fibrin(ogen) alpha C-domains. Biochemistry 2001; 40: 801-8.
15. Farrell DH, Thiagarajan P, Chung DW, Davie EW. Role of fibrinogen alpha and gamma chain sites in platelet aggregation. Proc Natl Acad Sci USA 1992; 89: 10729-32.
16. Dejana E, Zanetti A, Conforti LG. Biochemical and functional characteristics of fibrinogen interaction with endothelial cells. Haemostasis 1988; 18: 262-70.
17. Pereira M, Rybarczyk BJ, Odrljin TM, Hocking DC, Sottile J, Simpson-Haidaris PJ. The incorporation of fibrinogen into extracellular matrix is dependent on active assembly of a fibronectin matrix. J Cell Sci 2002; 115 (Pt 3): 609-17.
18. Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. Ann N Y Acad Sci 2001; 936: 11-30.
19. Weisel JW. Fibrinogen and fibrin. Adv Protein Chem 2005; 70: 247-99.
20. Sahni A, Khorana AA, Baggs RB, Peng H, Francis CW. FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis. Blood 2006; 107 (1): 126-31.
21. Shiose S, Hata Y, Noda Y, Sassa Y, Takeda A, Yoshikawa H, et al. Fibrinogen stimulates in vitro angiogenesis by choroidal endothelial cells via autocrine VEGF. Graefes Arch Clin Exp Ophthalmol 2004; 242 (9): 777-83.
22. Sahni A, Sahni SK, Francis CW. Endothelial cell activation by IL-1beta in the presence of fibrinogen requires alphavbeta3. Arterioscler Thromb Vasc Biol 2005; 25 (10): 2222-7.
23. Medved L, Nieuwenhuizen W. Molecular mechanisms of initiation of fibrinolysis by fibrin. Thromb Haemost 2003; 89: 409-19.
24. Hettasch JM, Greenberg CS. Fibrin formation and stabilization. In: Thrombosis and Hemorrhage. 2° ed. Baltimore (Maryland, EUA): Lozcalzo J and Schafer AI Eds.; 1998. p. 129-154.
25. Gorkun OV, Veklich YI, Medved LV, Henschen AH, Weisel JW. Role of the αC domains of fibrin in clot formation. Biochemistry 1994; 33: 6986-97.
26. Siebenlist KR, Meh DA, Mosesson MW. Protransglutaminase (Factor XIII) mediated cross-linking of fibrinogen and fibrin. Thromb Haemost 2001; 86: 1221-8.
27. Blombäck B, Carlsson K, Hessel B, Liljeborg A, Procyc R, Aslund N. Native fibrin gel networks observed by 3 D microscopy, permeation and turbidity. Biochim Biophys Acta 1989; 997: 96-110.
28. Lauricella AM, Quintana I, Kordich L. Effect of homocysteine thiol group on fibrin networks: Another possible mechanism of harm. Thromb Res 2002; 107: 75-9.
29. Collet JP, Park D, Lesty C, Soria J, Soria C, Montalescot G, et al. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed. Dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 2000; 20: 1354-61.
30. Weisel J, Veklich Y, Collet J Francis C. Structural studies of fibrinolysis by electron and light microscopy. Thromb Haemost 1999; 82 (2): 277-82.
31. Lukacova D, Matsueda GR, Haber E, Reed GL. Inhibition of factor XIII activation by an anti-peptide monoclonal antibody. Biochemistry 1991; 30 (42): 10164-70.
32. Mosesson MW, Hernandez I, Siebenlist KR. Evidence that catalytically-inactivated thrombin forms non-covalently linked dimers that bridge between fibrin/fibrinogen fibers and enhance fibrin polymerization. Biophys Chem 2004; 110 (1-2): 93-100.
33. Scheiner T, Jirouskova M, Nagaswami C, Coller BS, Weisel JW. A monoclonal antibody to the fibrinogen gamma-chain alters fibrin clot structure and its properties by producing short, thin fibers arranged in bundles. J Thromb Haemost 2003; 1 (12): 2594-602.
34. Lee KN, Jackson KW, Christiansen VJ, Chung KH, McKee PA. A novel plasma proteinase α2-antiplasmin inhibition of fibrin digestion. Blood 2004; 103 (10): 3783-8.
35. Vaziri ND, Kennedy SC, Kennedy M, Gonzalez E. Coagulation, fibrinolytic, and inhibitory proteins in acute myocardial infarction and angina pectoris. Am J Med 1994; 96 (6): 571.
36. Kaijzel EL, Koolwijk P, van Erck MG, van Hinsbergh VW, de Maat MP. Molecular weight fibrinogen variants determine angiogenesis rate in a fibrin matrix in vitro and in vivo. J Thromb Haemost 2006; 4 (9): 1975-81.
37. Siebenlist KR, Mosesson MW, Hernandez I, Bush LA, Di Cera E, Shainoff JR, et al. Studies on the basis for the properties of fibrin produced from fibrinogen-containing gamma' chains. Blood 2005; 106 (8): 2730-6.
38. Hamano A, Mimuro J, Aoshima M, Itoh T, Kitamura N, Nishinarita S, et al. Thrombophilic dysfibrinogen Tokyo V with the amino acid substitution of gammaAla327Thr: formation of fragile but fibrinolysis-resistant fibrin clots and its relevance to arterial thromboembolism. Blood 2004; 103 (8): 3045-50.
39. Marchi R, Carvajal Z, Meyer M, Soria J, Ruiz-Saez A, Arocha-Pinango CL, et al. Fibrinogen Guarenas, an abnormal fibrinogen with an Aalpha-chain truncation due to a nonsense mutation at Aalpha 467 Glu (GAA) - >stop (TAA). Thromb Res 2006; 118 (5): 637-50.
40. Hessel B, Silveira AM, Carlsson K, Oksa H, Rasi V, Vahtera E. Fibrinogenemia Tampere. A dysfibrinogenemia with defective gelation and thromboembolic disease. Thromb Res 1995; 78 (4): 323-39.
41. Sugo T, Endo H, Matsuda M, Ohmori T, Madoiwa S, Mimuro J, et al. A classification of the fibrin network structures formed from the hereditary dysfibrinogens. J Thromb Haemost 2006; 4 (8): 1738-46.
42. Blombäck B, Banerjee D, Carlsson K, Hamsten A, Hessel B, Procyk R, Silveira A, et al. Native fibrin gel networks and factors influencing their formation in health and disease. Adv Exp Med Biol 1990; 281: 1-23.
43. Okada M, Blombäck B. Calcium and fibrin gel structure. Thromb Res 1983; 29: 69-280.
44. Marx G. Divalent cations induce protofibril gelation. Am J Hemat 1988; 27: 104-9.
45. Kostelansky MS, Betts L, Gorkun OV, Lord ST. 2.8 A crystal structures of recombinant fragment D with and without two peptide ligands: GHRP binding to the "b" site disrupts its nearby calcium-binding site. Biochemistry 2002; 41: 12124-32.
46. Dang CV, Shin CK, Bell WR, Nagaswami C, Weisel JW. Fibrinogen sialic acid residues are low affinity calcium binding sites that influence fibrin assembly. J Biol Chem 1989; 264(25): 15104-8.
47. Hardy JJ, Carrell NA, McDonagh J. Calcium ion functions in fibrinogen conversion to fibrin. Ann N Y Acad Sci 1983; 408: 279-87.
48. Blomback B, Carlsson K, Fatah K, Hessel B, Procyk R. Fibrin in human plasma: gel architecture governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75: 521-38.
49. Ryan EA, Mochros LF, Weisel JW, Lorand L. Structural origin of fibrin clot rheology. Biophys J 1999; 77: 2813-26.
50. Nair CH, Azhar A, Wilson JD, Dhall DP. Studies of fibrin network structure in human plasma. Part II. Clinical application: Diabetic and antidiabetic drug. Thromb Res 1991; 64: 477-85.
51. Jörneskog G, Egberg N, Fagrell B, Fatah K, Hessel B, Johnsson H, et al. Altered properties of the fibrin gel structure in patients with IDDM. Diabetología 1996; 39: 1519-23.
52. Martínez J, MacDonald KA, Palascak JE. The role of sialic acid in the dysfibrinogenemia associated with leaver disease: distribution of sialic acid on the constituent chains. Blood 1983; 61: 1196-202.
53. Yoshida Y, Shiiki H, Iwano M, Uyama H, Hamano K, Nishino T, et al. Enhanced expression of plasminogen activator inhibitor 1 in patients with nephrotic syndrome. Nephron 2001; 88 (1): 24-9.
54. Weisel J, Veklich Y, Collet J Francis C. Structural studies of fibrinolysis by electron and light microscopy. Thromb Haemost 1999; 82 (2): 277-82.
55. Collet JP, Park D, Lesty C, Soria J, Soria C, Montalescot G, et al. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed. Dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 2000; 20: 1354-61.
56. Kolev K, Machovich R. Molecular and cellular modulation of fibrinolysis. Thromb Haemost 2003; 89; 610-21.
57. Gabriel DA, Muga K, Boothroyd EM. The effect of fibrin structure in fibrinolysis. J Biol Chem 1992; 267: 24259-63.
58. Sabovic M, Blinc A. Biochemical and biophysical conditions for blood clot lysis. Eur J Physiol 2000; 440 [Suppl]: R134-6.
59. Wu JH, Siddiqui K, Diamond S. Transport phenomena and clot dissolving therapy: an experimental investigation of diffusion-controlled and permeation-enhanced fibrinolysis. Thromb Haemost 1994; 72 (1): 105-12.
60. Mills JD, Ariens RA, Mansfield MW, Grant PJ. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 2002; 106 (15): 1938-42.
61. Fatah K, Silveira A, Tornvall P, Karpe F, Blomback M, Hamsten A. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996; 76 (4): 535-40.
62. Lim BC, Ariens RA, Carter AM, Weisel JW, Grant PJ. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 2003; 361 (9367): 1424-31. Erratum in: Lancet 2003; 361 (9376): 2250.
63. Lauricella AM, Quintana IL, Sassetti B, Castañón MM, Kordich LC. Influence of homocysteine on fibrin network lysis. Blood Coagul Fibrinol 2006; 17: 181-6.